High expectations for Amy Chevalier Efantis at Biogen

US biotech major Biogen (Nasdaq: BIIB) has brought in a woman with a background in both biopharma and the public sector as its new vice president of governmental affairs.

Amy Chevalier Efantis joins Biogen from privately-held German pharma Boehringer Ingelheim, where she led the company’s Washington-based government affairs and public policy team as executive director and head of office.

“Her experience will be invaluable in promoting access to life-changing therapies in multiple sclerosis, to implement new-born screening for spinal muscular atrophy and to raise awareness of the importance of early detection of Alzheimer's”